Treatment of hypercalcemia of tumoral origin with two diphosphonates

Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia. All patients responded well to the drugs afte...

Full description

Saved in:
Bibliographic Details
Published inSchweizerische medizinische Wochenschrift Vol. 110; no. 48; p. 1822
Main Authors Jung, A, van Ouwenaller, C, Chantraine, A, Courvoisier, B
Format Journal Article
LanguageFrench
Published Switzerland 29.11.1980
Subjects
Adult
Aged
Bone Resorption - prevention & control
Bronchial Neoplasms - complications
Diphosphonates - administration & dosage
Diphosphonates - therapeutic use
Esophageal Neoplasms - complications
Etidronic Acid - therapeutic use
Female
Humans
Hypercalcemia - drug therapy
Hypercalcemia - etiology
Male
Middle Aged
Neoplasms - complications
Ovarian Neoplasms - complications
Time Factors
Uterine Neoplasms - complications
Online AccessGet more information

Cover

More Information
Summary:Two diphosphonates, EHDP (disodium etidronate, or ethane-hydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in 8 patients who had had one or more episodes of malignant hypercalcemia. All patients responded well to the drugs after a time lapse of 2-10 days. Tolerance of the drugs was excellent. EHDP, and especially Cl2MDP, are promising agents for the treatment of hypercalcemia and the inhibition of bone resorption in malignant disorders.
ISSN:0036-7672